Financial Results Approval

The Board approved the Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2026.

Standalone Financial Results (₹ in lakhs):

  • Total Income: ₹19,860
  • Total Expenses: ₹15,105
  • Profit before tax and exceptional items: ₹4,755
  • Exceptional items (Income): ₹351 (ECL allowance reversal on loans to wholly owned foreign subsidiaries)
  • Profit before tax: ₹5,106
  • Tax expense: ₹(1,386) [Current tax: ₹1,378, Current tax adjustment for earlier years: ₹(2,764)]
  • Net profit for the period: ₹6,492
  • Other comprehensive income: ₹0
  • Total comprehensive income: ₹6,492
  • Paid-up equity share capital: ₹1,956
  • Earnings per share (Basic): ₹3.32 (not annualized)

Consolidated Financial Results (₹ in lakhs):

  • Total Income: ₹46,891
  • Revenue from operations: ₹46,578 [Net Sales: ₹39,001, Service Income and License fees: ₹7,577]
  • Other Income: ₹313
  • Total Expenses: ₹37,682
  • Profit before share of profit of JV/associates, exceptional items and tax: ₹9,209
  • Share of Profit/(loss) of Joint venture and associates, net of tax: ₹596
  • Profit before tax and exceptional items: ₹9,806
  • Exceptional items: ₹0 (Previous quarter: ₹2,502)
  • Profit Before Tax: ₹9,806
  • Tax Expense: ₹(283) [Current tax: ₹2,253, Current tax adjustment for earlier years: ₹0, Deferred tax: ₹(2,536), Deferred tax adjustment for earlier years: ₹0]
  • Profit for the Period before non-controlling interest: ₹10,088
  • Share of (loss)/profit attributable to non-controlling interest: ₹0
  • Profit after taxes attributable to owners: ₹10,088
  • Other comprehensive income: ₹1
  • Total comprehensive income: ₹10,090
  • Paid-up equity share capital: ₹1,956
  • Earnings per share (Basic): ₹5.16 (not annualized)
  • Earnings per share (Diluted): ₹5.16 (not annualized)

Management Appointments

  • Appointment of Mr. Sharath Reddy Kalakota (DIN: 03603460) as Whole-time Director of the Company, liable to retire by rotation, subject to member's approval in the ensuing Annual General Meeting (AGM).
  • Mr. Kalakota, aged 58, is a Post graduate in Pharmacy from BITS Pilani and has over 3 decades of experience in API manufacturing and operations.
  • He is not related to any other directors and is not debarred from holding office.

Subsidiary Matters

  • Payment of remuneration to Mr. Madhav Vishnukant Bhutada (DIN: 08222055), Non-Executive Director of Shilpa Biologicals Ltd (SBPL), a material subsidiary, by way of commission up to 1% net profits of SBPL effective 1 April 2026.
  • Further to communication dated 3rd June 2026, Shilpa Biocare Private Limited (wholly owned subsidiary) proposed Strategic Long-Term Equity Partnership in Gate2Brain (G2B) with investment aggregating up to EUR 7 million through a combination of cash infusion/equity for services/development of projects.

Annual General Meeting

  • The 39th AGM is scheduled for Friday, 11th September 2026 at 11:00 AM through VC/OAVM.
  • Record date for determining shareholders entitled for payment of final dividend for FY 2025-26 (if declared) and cut-off date for e-voting is Friday, 4th September 2026.
  • Remote e-voting will be conducted by KFin Technologies Limited from 7th September 2026 (9:00 AM) to 10th September 2026 (5:00 PM).
  • Mr. Santosh Kumar Gunemoni of M/s VCAN & Associates appointed as Scrutinizer.

Financial Statement Notes

1. Results reviewed by Audit Committee and approved by Board on 5th August 2026. Statutory auditors carried out Limited Review and issued unmodified opinion.

2. Prepared in accordance with Ind AS and SEBI LODR Regulations.

3. Exceptional Items:

  • Standalone: ECL allowance reversal of ₹351 on loans to wholly owned foreign subsidiaries
  • Consolidated: No exceptional items for current quarter (previous quarter included various items totaling ₹2,502)

4. Implementation of new Labour Codes effective November 21, 2025 resulted in incremental gratuity liability charge, presented under Exceptional Items in previous periods.

5. National Company Law Tribunal, Bengaluru sanctioned Scheme of Merger of Shilpa Therapeutics Private Limited (wholly owned subsidiary) with appointed date as April 1, 2025. Previous period figures have been restated accordingly.

6. Company allotted 9,77,90,908 fully paid-up Bonus Equity Shares on 7.10.2025 in 1:1 ratio. EPS for previous periods adjusted for bonus issue.

7. Company evaluated tax liability under old and new regime and calculated tax as per Section 200 of Income-tax Act, 2025 under new regime. Resultant one-time deferred tax liability reversal of ₹2,684 lakhs recognized in P&L.

8. Operating segment is "Pharmaceuticals" with one reportable segment.

9. Figures for quarter ended March 31, 2026 are balancing figures between audited annual figures and published unaudited YTD figures up to December 31, 2025.

10. Prior period figures reclassified where required.

Auditor's Review Report

  • B N P S And Associates LLP conducted limited review of both standalone and consolidated financial results.
  • Nothing came to their attention causing belief that the statements contain material misstatement.
  • Consolidated results include 14 subsidiaries, 2 joint ventures, and 3 associates.
  • Financial statements of 1 subsidiary reviewed by other auditor, 8 subsidiaries not reviewed by any auditor, and 1 foreign associate's interim financial statements not concluded.